Taken together, our data using xenografts, PDX models, and syngeneic and genetic mouse models with intact immunity provide the important proof of principle that targeting SIRPγ is a promising strategy for NSCLC treatment. This evidence concerns the gene SIRPG and non-small cell lung carcinoma.